AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05193864 — intervention group
Intervention type: DEVICE
Intervention: Device: JVPHome and ultrasound
Description: Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
Study NCT01739478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Packing of abscess cavity
Study NCT01739478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External dressing
Description: Application of external dressing whilst abscess cavity heals
Study NCT01739478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: External dressing
Description: Application of external dressing whilst abscess cavity heals
Study NCT05268939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 & Flu A/B test
Description: Swab Samples for Diagnostic test
Study NCT05268939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 & RSV test
Description: Swab Samples for Diagnostic test
Study NCT06123104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusion of blood flow diagnosed by Point of Care UltraSound (POCUS)
Description: Tourniquets will be applied until peripheral blood flow occlusion is achieved. Total intervention time: up to 60 seconds
Study NCT06123104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusion of blood flow diagnosed by Point of Care UltraSound (POCUS)
Description: Tourniquets will be applied until peripheral blood flow occlusion is achieved. Total intervention time: up to 60 seconds
Study NCT06161987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early comprehensive rehabilitation
Description: Patients randomized to the rehabilitation intervention group will be offered comprehensive rehabilitation plan containing 18 sessions of a structured outpatient-based exercise program over 6 weeks (3 times per week).
Study NCT04363112 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mini Kid II
Description: Mini Kid II (Mini International Neuropsychiatric Interview ) is a standardised, hetero mental health questionary for children, according to DSM IV. Mini Kid II will be administered to children between day 3 and 7 during the study.
Study NCT05356494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural drainage
Description: (Group A will be treated with postural drainage)
Study NCT05356494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure
Description: (Group B will be treated with positive expiratory pressure technique).
Study NCT04324554 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI of the right knee
Description: An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
Study NCT03747328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: nanoparticle albumin bound sirolimus
Study NCT06466941 — intervention group
Intervention type: PROCEDURE
Intervention: regional anesthesia
Description: Patients who underwent surgery and received an epidural or peripheral nerve block
Study NCT06466941 — intervention group
Intervention type: PROCEDURE
Intervention: no regional anesthesia
Description: Patients who underwent surgery and did not received an epidural or peripheral nerve block
Study NCT06466941 — intervention group
Intervention type: OTHER
Intervention: acute pain consultation
Description: Patients who underwent surgery and had a perioperative (preop, intraop, or postop) acute pain consultation
Study NCT06466941 — intervention group
Intervention type: OTHER
Intervention: no acute pain consultation
Description: Patients who underwent surgery and did not have a perioperative (preop, intraop, or postop) acute pain consultation
Study NCT06635824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: IV infusion
Study NCT06635824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT06635824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study NCT05142865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
Study NCT05142865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m2 IV continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
Study NCT05142865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min IV on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6)
Study NCT05142865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2，continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
Study NCT05142865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250 mg given orally, once daily in 21-day cycle
Study NCT05328258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Embonate
Description: 11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug.~3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug.
Study NCT06581432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib
Study NCT05940194 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVIVAC vaccine
Description: For prevention Covid-19
Study NCT05940194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIVAC vaccine
Description: For prevention Covid-19
Study NCT06446063 — intervention group
Intervention type: OTHER
Intervention: Test product
Description: Twice daily applications The product is applied to the entire face.
Study NCT06446063 — intervention group
Intervention type: OTHER
Intervention: Control Product
Description: Twice daily applications The product is applied to the entire face.
Study NCT06506032 — intervention group
Intervention type: DRUG
Intervention: Intravenous Vancomycin administration
Description: Vancomycin was administered to the patients at the discretion of the physician
Study NCT06506032 — intervention group
Intervention type: OTHER
Intervention: Standard postoperative therapy
Description: The patients received standard postoperative therapy
Study NCT05086757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRRP
Description: Receive TRRP services
Study NCT05086757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants will receive an educational flyer with service referrals
Study NCT06055842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: over-denture
Description: implant retained overdenture prosthesis.
Study NCT05223231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-019 Injection
Description: initial dose-MTD
Study NCT05223231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody injection
Description: provide medicine base on needs
Study NCT06318806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy is a type of treatment that can help individuals experiencing mental health conditions and emotional challenges.
Study NCT06318806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy is a type of treatment that can help individuals experiencing mental health conditions and emotional challenges.
Study NCT05498233 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxylamine + Pyridoxine
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Study NCT04277117 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: Phase 1 (6 months)~• Educational materials on such topics as healthy eating for diabetes.
Study NCT04277117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medically tailored meals - Daily delivery with human interaction
Description: Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 MTM a week: mix of hot and frozen, and 5-10 snacks per week. Meals and snacks offer approx. 1200 kcal per day.~* Delivery: 3 to 5x per week. Each delivery day, one meal is warm, the other is frozen. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (at minimum in-person hand-off \& visual check) with the participant.
Study NCT04277117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medically tailored meals - Weekly delivery with no human interaction
Description: Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 frozen MTM and 5-10 healthy snacks (with the goal of providing 2 meals and 1-2 snacks for 5 days of the week). Meals and snacks offer approx. 1200 kcal per day. Nutritionally similar and frequently the same meal as that delivered in the daily delivery arm.~* Delivery: 1x per week shipment.~* Engagement: Meals are shipped to the participant's home. No human engagement.
Study NCT04277117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medically tailored meals - Standard MOWCTX delivery with human interaction
Description: Phase 2 (6 months)~* Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~* Delivery: 2 to 4x a week (depending on participant availability), including daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day or more (depending on the 2 to 4x a week delivery schedule participant is on) also including 1 frozen MTM to total 5 meals per week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~* MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care).
Study NCT04277117 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medically tailored meals - Standard MOWCTX delivery with human interaction
Description: Phase 2 (6 months)~* Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~* Delivery: 2 to 4x a week (depending on participant availability), including daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day or more (depending on the 2 to 4x a week delivery schedule participant is on) also including 1 frozen MTM to total 5 meals per week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~* MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care).
Study NCT04681833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo
Description: Low Repeat Dose
Study NCT04681833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)
Description: High Repeat Dose/High Repeat Multiple Dose
Study NCT04681833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid diluent/Lyophilised Powder
Study NCT04527380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT04527380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study NCT06481592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with lifileucel, followed by IL-2.
Study NCT04949100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief
Description: * Duration: 60 minutes.~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Frequency: Each lead delivers a dual channel microcurrent of 10 and 40 Hz simultaneously.~* Amperage: Adjusted according to BMI: 100 μA for an underweight BMI less 20, 300μA for an overweight BMI greater than 30, and 200μA for normal BMI (20-30). Amperage may be adjusted to 20-300 μA according to comfort.~* Positioning: The patient remains seated for the first 10 minutes with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment.
Study NCT04949100 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief
Description: * Duration: 60 minutes.~* Frequency: None~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Amperage: None~* Positioning: The patient remains seated for the first 10 minutes, again, with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment.
Study NCT06345950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal Glutathione
Description: A maximum single dose of 500 mg glutathione (hard gel capsules)
Study NCT06345950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Glutathione
Description: A maximum single dose of 500 mg glutathione (hard gel capsules)
Study NCT06345950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Micellar Glutathione (Lipomicel)
Description: A maximum single dose of 600 mg glutathione (soft gel capsules)
Study NCT05489809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal extubation with suctioning
Description: General anestheisa is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying suctioning.
Study NCT05489809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal extubation with positive pressure
Description: General anesthesia is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying positive pressure.
Study NCT05969548 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active 1200-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
Study NCT05969548 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active 2400-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
Study NCT05328258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride solution 0.9%
Description: One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
Study NCT05969548 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active 3600-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
Study NCT05969548 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham 1200-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
Study NCT05969548 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham 2400-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
Study NCT06285409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin first bolus 10-8 M (equivalent to 100 mcg) will be added to the muscle bath to create ex-vivo environment similar to Cesarean delivery, and after 20 minutes the baths will be washed three time with physiological salt solution (PSS).
Study NCT06285409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin first bolus 10-8 M (equivalent to 100 mcg) will be added to the muscle bath to create ex-vivo environment similar to Cesarean delivery, and after 20 minutes the baths will be washed three time with physiological salt solution (PSS).
Study NCT06285409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 10-5M will be added to all strips for 2 hours to induce desensitization.
Study NCT06285409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 10-5M will be added to all strips for 2 hours to induce desensitization.
Study NCT06285409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-5 M to 10-5 M
Study NCT06285409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Increasing concentrations of oxytocin from 10-10 M to 10-5 M
Study NCT06285409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergonovine
Description: Increasing concentrations of ergometrine from 10-10 M to 10-5 M
Study NCT06285409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboprost
Description: Increasing concentrations of carboprost from 10-10 M to 10-5 M
Study NCT05252468 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TaffiX™
Description: Personal nasal powder spray.
Study NCT05252468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaffiX™
Description: Personal nasal powder spray.
Study NCT05033327 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition and Exercise app
Description: Personalized, home-based, interactive therapy app
Study NCT05596331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: eye-tracker
Description: Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity
Study NCT06366568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoride toothpaste containing 1450 ppm of MFP in a PCC base and eugenol gum product
Description: PARTICIPANTS WILL USE A EUGENOL BASED product PRIOR TO TOOTHBRUSHING
Study NCT06366568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluoride toothpaste containing 1450 ppm of MFP in a PCC base
Description: toothbrushing 2x a day for 2 minutes each time
Study NCT05999136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulses diet
Description: Subjects in the PulD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PulD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with servings of pulses.
Study NCT05999136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant proteins diet
Description: Subjects in the PPD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PPD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with a mixture of pulses and plant-based meat substitutes.
Study NCT05999136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Habitual diet
Description: Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
Study NCT05969548 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham 3600-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.